Murouj A. Almaghrabi<sup>1</sup>, Wejdan E. Rahali<sup>1</sup>, Ahad S. Babkier<sup>1</sup>, Sadeem E. Bukhari<sup>1</sup>, Mokhtar M. Shatla<sup>2</sup>.

<sup>1</sup>Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. <sup>2</sup>Associate professor, Department of Community Medicine and pilgrimage health, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.

### ABSTRACT

**Background:** The strongest COVID-19 control solution is an effective vaccine. Several factors affect COVID-19 vaccine acceptance by the general population. Public health officials and practitioners must recognize all obstacles that may discourage people from obtaining COVID-19 vaccines. The present study aimed to measure the extent of community acceptance of taking the COVID-19 vaccine in Saudi Arabia, as well as to assess the limitations, concerns, and obstacles that is related to the vaccine.

**Methods:** A cross-sectional study of a sample consisting of 1400 participants living in Saudi Arabia assessed socio-demographic characteristics, general characteristics of the vaccinated participants, and participants' acceptance, concerns, and obstacles related to COVID-19 vaccination.

**Results:** Most participants were females (63.1%) and from the western region of Saudi Arabia (81.2%). Nearly equal number was reported between vaccinated and non-vaccinated participants with COVID-19 vaccination (45% and 55% respectively). Exact of 324 participants reported obstacles that prevent them from getting the vaccine, in which the highly reported item was lack of information about the vaccine (21.6%). A total number of 1,796 participants reported few concerns, in which the most common item was health concern (43.4%), followed by misleading ideas and beliefs (35.4%). A recorded statistical significance p-value was determined between the participants who received COVID-19 vaccination and the gender, nationality, place of residence, and working in government sector (P=0.002, 0.002, 0.001, and 0.011, respectively).

**Conclusions:** Awareness of COVID-19 vaccination is still lacking. Thus, a targeted health educational programs are needed to increase the individuals convince and reduce the fears about the vaccination.

Keyword: Acceptance, COVID-19, obstacles, Saudi Arabia, vaccination.

### Introduction

Coronavirus disease 2019 (COVID-19) is a highly contagious respiratory illness caused by a novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus. The World Health Organization (WHO) officially declared COVID-19 to be a pandemic on March 11, 2020. COVID-19 was first reported in Wuhan, China [1] and has since rapidly spread globally in a short period of time [2] because the virus is extremely infectious, it spreads quickly and evolves over time in humans [1].

Access this article online		
Quick Response Code: Website:		
	www.smh-j.com	
	DOI:	
	10.54293/smhj.v1i1.18	

Virus transmission can happen via human-to-human contact or through droplet transfer, cough, or sneeze [3, 4]. The goal of preventative measures is to limit and control the spread of the infection. Social distancing, such as stopping large public or private meetings [2], widespread closures of public and commercial spaces [5], wearing masks and gloves, and avoiding unnecessary travels and visits, are all ways to decrease the risk of infection [2]. While efforts to promote social distancing and masking have been effective,

Address for correspondence: Murouj A. Almaghrabi, Department Of Medicine, College of Medicine, Umm Al-Qura University, KSA. <u>E-mail: murouj@outlook.com</u> Received: 1 November 2021 | Accepted: 22 November 2021

This is an open access article by SMHJ is licensed under Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0)

Please cite this article as: Rahali W, Almaghrabi M, Babkier A, Bukhari S, Shatla M. The Acceptance, Concerns, and Obstacles related to COVID-19 Vaccination among the General Society in Saudi Arabia: COVID-19 vaccination perception among the public. SMHJ [Internet]. 2021;1(1):14-25.



© Saudi Medical Horizons Journal

They have had economic and psychological consequences. The strongest COVID-19 control solution is an effective vaccine [5], therefore vaccination may be used to prevent infection or to lessen the severity of the disease, as well as viral shedding and transmission [6], there are 30 vaccines in clinical trials as of late August 2020, with over 200 in different stages of development [7]. In Saudi Arabia, there are two different types of vaccination used. Firstly, the non-replicating viral vectors (NRVV) from University of Oxford/AstraZenec Organization, Adenovirus-based vaccines are the most commonly used virally vectored candidates for non-replicating SARS-CoV-2 vaccines, after injection NRVV vaccines caused minor local responses, such as swelling and redness, as well as systemic symptoms such as malaise, fatigue, fever, and headache, which all went away within 96 hours. The second type is messenger ribonucleic acid (mRNA) vaccine from Pharma/Pfizer Organization. BioNTech/Fosun Nucleic acid vaccine candidates are usually quicker and less expensive to produce than protein subunit vaccines, so many mRNA-based SARS-CoV-2 vaccine candidates have been created, although these vaccines caused mild side effects after the first dose, such as fatigue, chills, headache, myalgia, and localized pain at the injection site, side effects worsened as the dosage was increased, and booster doses in some patients caused moderate to serious local and systemic responses [8]. Hence, public health practice suggests that a sufficient number of people must be vaccinated to control an outbreak like COVID-19 [5]. A previous study has surveyed 13,426 people in 19 countries in June 2020 to see what factors affect COVID-19 vaccine acceptance. In which 71.5 percent of respondents showed they would be very or very likely to get the COVID-19 vaccine [9]. Public health officials and practitioners must recognize all obstacles that may discourage people from obtaining the approved vaccines. Infectious disease control in the United States (US) and around the world has established a wide range of obstacles that can obstruct vaccine uptake, resulting in disease control failure. The barriers were separated into two types: structural and psychological. First: structural barriers, which are the structural problems that can make it difficult for individual people to get vaccines: Time, transportation, expense, and clinic or outlet location are examples of structural barriers that affect one's ability to access a service. Second: the attitudinal barriers, which are the attitudes or expectations that affect at-risk individuals' ability to seek out and/or

accept services. They have also included the beliefs about the communicable disease, vaccine beliefs, fear, and trust in healthcare and government agencies in the sense of vaccination [5]. Early detection of the population acceptance towards COVID-19 vaccination is necessary, which directly affect the quality of life for the community. To the best of our knowledge, there is no study in Saudi Arabia that has previously discussed this issue. Since there is a remarkable number of people did not receive the vaccine of COVID-19 in the Kingdome of Saudi Arabia (KSA) population although reservation is available for vaccination for everyone. Therefore, assessing this situation in depth is required. The present study aims to measure the extent of community demand for taking the COVID-19 vaccine in KSA, as well as to assess the limitations, concerns, and obstacles that is related to it.

#### Methods

We conducted this online-based cross-sectional study for citizens and residents in Saudi Arabia. A sample of 1400 individuals was collected randomly through a self-administered online questionnaire from 18 March 2021 to 24 March 2021. All individuals who are eligible to answer the questionnaire were invited to participate in the study. We have excluded individuals below the age of 15 years. We used OpenEpi version 3.0 [10] to calculate the required sample size for this study. In consideration of the following: the population size of Saudi Arabia residents is about 35,013,414 people [11].Keeping the Confidence Interval (CI) level at 99% and considering anticipated % of frequency as 50% and taking design effect as 1.0. The sample size was 664 participants. In case of data loss, a total sample size of 700 participants was required. However, the final collected data included 1,400 participants. The questionnaire of the present study has been developed by reviewing the previous literature. Then, it was sent to a group of certified doctors in the speciality to check its validity. This questionnaire consists of several items distributed over three main parts: 1) First: general characteristics of the participants, including gender, age, nationality, educational level, occupation, residence place, past medical history including previous history of COVID-19 infection, and the received vaccines. 2) Second: four items to discover the general characteristics of the vaccinated participants. 3) Last part: five items to assess the participants' acceptance, concerns, and obstacles related to COVID-19 vaccination.

Ethical approval of this study was obtained from the Institutional Review Board (IRB) at Umm Al-Qura

University (UQU), Makkah, Saudi Arabia (code HAPO-02-K-012-2021-08-722). Prior to answering the questionnaire, electronic informed consent was gained from each participant, and they were informed that it is a voluntary effort, and they can withdraw at any time. The confidentiality of the participants was ensured. No personal data (such as names or phone numbers) were obtained from any participant.

#### Statistical analysis

The data analysis was performed with Statistical Package for the Social Sciences (SPSS), version 22 (IBM, Armonk, NY, USA). The study graphs were performed using Microsoft Excel software. All statistical analyses were performed using two-tailed tests with an alpha error of 0.05. Statistical significance was set at P < 0.05. We used frequencies and percentages to describe all categorical data of the participants. Crosstabulation was performed between reviving COVID-19 vaccination and demographic data of the participants to detect the most significant variables based on Pearson's chi-squared test.

### Results

Socio-demographic characteristics of the participants A total number of 1400 participants were included in our study. (Table 1) demonstrates the sociodemographic characteristics of the participants in which nearly half of them were between the ages of 16-36 years (680, 48.6%), with females predominate (884, 63.1%). The majority of responders were Saudis (1314, 93.9%) while only view numbers were recorded from non-Saudi participants (86, 6.1%). Most of the participants were from the western region (1137, 81.2%), not known to have any illness (1,034, 73.2%), and with an educational level of bachelor's degree (781, 55.8%). Regarding occupation, exact number of 486 participants were Retired/ non-worker/ Housewife (34.7%), followed by 347 students (24.8%). The least recorded occupation in our population was a private job (32, 2.3%). Close percentages were observed between workers in the government sector and those not working in it (30.6% and 28.6%, respectively). Among all respondents, only view numbers have recorded a previous history of COVID-19 infection (204, 14.6%) while the majority have no history of infection (1196, 85.4%). (Figure 1) represents the participants' commitment regarding different types of vaccinations. In which more than half of the participants were not restricted in receiving flu vaccine annually (965, 69%) in comparison to 435 participants who were restricted to

receive the flu vaccine annually (31%). In addition,

most of the participants does not receive the

meningitis vaccine every 5 years (1,233, 88%) while only a view number of participants were committed to receive it (167, 12%). In contrary to COVID-19 vaccination, close numbers were recorded between vaccinated and non-vaccinated participants. Hence, non-vaccinated participants were slightly higher in number compared to vaccinated participants (775, and 625, 45%, respectively). General 55% characteristics of the vaccines and their side effects Our study recorded a total of 625 vaccinated participants. (Table 2) presents the general characteristics of the vaccines and their side effects among the participants. In which, number of vaccinated participants with Pfizer were 325 (52%), while AstraZeneca-Oxford were 300 participants (48%). The Purpose of getting vaccinated varied between participants, the most reason was desire and conviction (548, 87.7%) followed by vaccination affordability (12, 1.9%), some for their job requirement (30, 4.8%) others for their family desire (9, 1.4%) also as a traveling requirement (22, 3.5%), then as a protection for the family (1, 0.2%), additionally for preventing covid-19 complication (1, 0.2%), and for multiple purposes (1, 0.2%), and lastly for no purpose (1, 0.2%). According to the vaccine side effects, more than a half of the participants suffered from the presence of side effects (343, 54.9%), and the others did not have any side effects (282, 45.1%). Side effects have been categorized into generalized and systematic, considering generalized it was fever (232, 67.7 %), body tremor (76, 22.2 %), fainting (3, 0.9 %), uterine pain (1, 0.3 %), swelling of mouth and face and neck (6, 1.7 %). Systematically side effects were recognized as follows, dermatological (231, 67.3 %), gastrointestinal (129, 37.6 %), neurological (249, 72.6 %), respiratory (21, 6.2 %), and musculoskeletal (282, 82.3 %).


# Acceptance, concerns, and obstacles related to the vaccination

Exact number of 371 participants were accepted the idea of coronavirus vaccination (47.9%). On the other hand, 142 participants were refusing it (18.3%). In regard to the barriers, 599 (77.3%) participants have no barriers to taking the vaccine and 176 (22.7%) having barriers. A 262 (33.8%) are still confused about taking the vaccination. (Table 3) Summarize the results. (Table 4) represents the number of participants who reported obstacles that prevented them of getting the vaccine. From a total of 324 response, the most report obstacle was lack of information and education about COVID-19 and its vaccination and about how to use the application (70, 21.6%), followed by

conflicting information concerning the vaccine's safety (62, 19.1%), then followed by having health problems or allergy (58, 17.9%), after that multiple available types of vaccination (46, 14.2%), then taking a long time to obtain an appointment and being far away from the centres (29, 9.0%). The least reported obstacles were 'others' (7, 2.2%), followed by Covid-19 was previously diagnosed in less than 6 months (8, 2.5%), then Parental refuse (12, 3.7%), after that do not have a health reason to be vaccinated (15, 4.6 %), followed by lactating and pregnant women (17, 5.2 %). The total number of concerns reported by the participants were 1,796, most common concern reported by them was a health concern (779,43.4%), followed by misleading ideas and beliefs (635,35.4%), followed by vaccine trial and efficacy (213,11.8%) and the least common concerns reported by participants was information circulated on social media (106,5.9%), followed by virus strains (63,3.5%). All results are shown in (Table 5).

## Association between receiving COVID-19 vaccination and demographic data

(Table 4) demonstrates the association between COVID-19 receiving vaccination and the demographic characteristics of the participants. Among participants who did not receive the vaccine, females recorded higher numbers compared to male participants (67.4% and 32.6%, respectively). On the other hand, females were detected to receive the vaccine more than males (57.9% and 42.1%, respectively) with a recorded statistical significance (P=0.002). As for nationality, 96.5% of the vaccinated participants were Saudis compared to 3.5% of non-Saudis, with statistical significance (P=0.002). Regarding place of residence, 85.1% of the vaccinated participants were from western region followed by 11.5% of the vaccinated participants from central region. On the other hand, 78.1% of the western region were non vaccinated with historical statistical significance (P=0.001). Other demographic variables associated with receiving COVID-19 vaccination are shown in (Table 6).



*Figure 1: Participants Practice Regarding Different Vaccinations (n=1400).* 

#### Discussion

The current study is among the first studies that represented an assessments of COVID-19 vaccination behavior in KSA. In which the study revealed almost the same number between vaccinated and nonvaccinated participants. The most common obstacle of COVID-19 vaccination reported by non-vaccinated participants is their belief of conflicting information concerning the vaccine's safety. While the health concerns reported to be the most concerns that prevent people to take the vaccine.

### Socio-demographics of the participants

The participants' distribution on the two genders was semi-equal with predominance to the female gender. As most of our participants were reported to be Saudis (93.9%), generalizability of the current results will be more accurate on the Saudis sample not residents of different nationalities in the KSA. Participants were included from all regions of KSA, and various ages ranged from 16 years to more than 57 years were also included in the study which will contribute to extracting different opinions from different generations. However, the vast majority of the study's participants were highly educated which may affect generalizing the results. We recommend further studies to be conduct on low educated populations in Saudi Arabia to better understand their opinion, acceptance, concerns, and obstacles related to COVID-19 vaccination.

### General characteristics of the vaccinated participants and the reported side effects

We gathered data from people who got either Oxford-AstraZeneca or Pfizer BioNTech COVID-19 vaccinations in Saudi Arabia, total of 625 received AstraZeneca-Oxford 325 (52%) and Pfizer 300 (48%) vaccines. In our survey, 54.9 % said they had suffered some side effects and 282 (45.1%) they didn't have any side effects. The most prevalent adverse effects were fatigue (72.9%), fever (67.6%), pain in site of injection (61.5%), and headache (55.1%), after that nausea (29.7%). Unlike other studies, in UK they discovered that systemic side effects, such as headache and fatigue, impacted fewer than one out of every four people and were less prevalent in the population than clinical studies predicted [12]. In our study, most of the participants who took the Oxford-AstraZeneca vaccine reported considerably more side effects than those who received the Pfizer-BioNTech vaccine, according to our findings. As can also be seen in recent study done in Saudi Arabia [13].

Acceptance of COVID-19 vaccine

As reported previously in the current study, six hundred twenty-five individuals (44.6%) have been vaccinated while a total of 775 individuals (55.4%) have not been vaccinated and they were divided into 371 (26.5%) who were willing to take the vaccine, 262 (18.7%) might take the vaccine, and 142 (10.2%) are refusing the vaccine (Table 7).

In comparison to our study, a previous study in the US reported that 450 (67%) of 672 respondents would accept the COVID-19 vaccine. Despite the fact that a COVID-19 vaccine was accepted by 67 % in the trial, there were significant demographic and geographic differences in vaccination acceptance [14]. Further study in Saudi Arabia included 992 attendees from four major cities (Riyadh, Jeddah, Dammam, and Abha) as well as some minor cities. Of the 992 attendees, 642 (64.7%) accepted the COVID-19 vaccine, 70 (7.0%) rejected the vaccine, and 280 (28.2%) were hesitant about COVID-19 vaccine if it is available [15].

#### **Barriers of receiving COVID-19 vaccine**

From a total of 599 (77.3%) individuals who were non-vaccinated, exact of 775 (55.4%) had no barriers for taking the vaccine while 176 (22.7%) had some. Vaccine variety types and COVID-19 strains issues 62 (35.2%) was the major barrier effecting the participants, vaccine production issues 1 (0.6%), Medication Issues 1 (0.6%) and Religious Believes 1 (0.6%) were the least barriers affecting them see (Table 8) for more details.

Previous evidence placed in Tanta and Kafrelsheikh Universities in Egypt among medical students, The most relevant barriers of COVID-19 vaccination were insufficient information regarding adverse effects of the vaccine (potential 74.2% and unknown 56.3%), insufficient information regarding the vaccine itself (72.8%), financial cost hindrance if the vaccine is not free (68.0%), and insufficient trust in the vaccination source (55.1%) [16].

#### **Concerns of COVID-19 vaccine**

The most popular concern in this study respectively, Harmful and non-beneficial issue 388 (77.6%) Severe side effects 282 (52.5%) Trials aren't over 208 (38.7%) Leads to other health conditions 192 (35.7%) Leads to death 135 (25.1%) Effects Genes 116 (21.6%) Only a trial 113 (21%) Fear from Social Media trending 106 (19.7%) Aimed to eliminate humans 78 (14.5%) New strains of COVID-19 61 (11.3 %) Profit vaccine 57 (10.6%) Becomes an annual vaccine 49 (9.1%) Allergy or other health condition 5 (1%) Strange disease and vaccine existence 3 (0.6%) No suitable vaccine yet 1 (0.2%) Fear of being infected while vaccinated 1 (0.2%).

### Association between receiving COVID-19 vaccination and demographic data

As shown in Table 6, a statistically significant association were reported between the gender and the demand for receiving COVID-19 vaccination as the females were predominated group (884, 63.1%). The reason may be due to the female keenness to take precautions and adhere to preventive measures and their sense of responsibility, as many studies reviled the same results even with different health issues [17-19]. Understanding the sociodemographic characteristics in relation to COVID-19 vaccination receiving may aid in increasing global immunization program uptake to combat future pandemics. Hence, the socio-demographic characteristics of the current study were predominated group between the ages of 16-36 years (680, 48.6%) followed by the ages of 37-56 years (535, 38.2%) followed by 57 years and more (185,13.2%). The participants were from all throughout Saudi Arabia., most of them were from the western region (1,137, 81.2%), followed by Central Region (159,11.4%) and Eastern Region (45,3.2%) and Southern Region (35,2.5%) and Northern Region (24,1.7%). As reported previously, the educational level of the participants was mostly bachelor's degree (781, 55.8%) followed by High school/ diploma (377,26.9%) and master or higher degree (192,13.7%). Only minor percentage of participants were elementary/ intermediate School (50,3.6%). As a comparison, the recent study that has been conducted in the four major cites (Riyadh - Dammam - Jeddah -Abha) in Saudi Arabia [15] reported the sociodemographic characteristics of a number of 992 participants, they reported the predominate group to be between the ages of 26-35 years (436,43.9%) followed by ages of 18-25 years (264,26.6%), ages of 36-45 years (230,24%) and ages 45 and more (53,5.3%). Most of their responses were graduate individuals (497, 50.1%), post-graduate (199, 20%), followed by diploma (153,15.4%), and high school students (143,14.4%). The variety of those populations revealed almost the same conclusion which states that educational health programs are needed to increase the awareness of the safety of COVID-19 vaccination among the community individuals. In other recent study showed the different in acceptance rate between countries [20], it was previously reported in China (91.3-72.6%), Indonesia (93.3%), Malaysia (94.3%) Denmark (80.0%), UK (90.1-64.0%), Canada (68.7-80.0%), Turkey (69.0%) Nigeria (65.2%).

Socio-demographic data		No	%
Gender	Female	884	63.1%
Genuer	Male	516	36.9%
A	16-36 years	680	48.6%
Age	37-56 years	535	38.2%
	57+ years	185	13.2%
NT /1 11/	Saudi	1,314	93.9%
Nationality	Non-Saudi	86	6.1%
	None	1,034	73.2%
Past Medical History (PMH)	Endocrine Conditions *	253	17.9%
	Respiratory Conditions **	72	5.1%
	Others ***	53	3.8%
	Western Region	1,137	81.2%
	Central Region	159	11.4%
Place of Residence	Eastern Region	45	3.2%
	Southern Region	35	2.5%
	Northern Region	24	1.7%
	Elementary/ Intermediate School	50	3.6%
	High school/ Diploma	377	26.9%
	Bachelor's degree	781	55.8%
Educational level	Master or higher degree	192	13.7%
	Student	347	24.8%
	Retired/ non-worker/ Housewife	486	34.7%
Occupation	Health care provider	118	8.4%
	Office work	313	22.4%
	Field work	104	7.4%
	Private job	32	2.3%
	Yes	429	30.6%
Work in a Government Sector	No	400	28.6%
	Do not work	571	40.8%
Burning Line of COMP 10	Yes	204	14.6%
Previous history of COVID-19	No	1,196	85.4%

#### Table 1: Socio-demographics and sample

\* Endocrine conditions: including Hypertension (HTN), Diabetes Mellitus (DM), Thyroid Diseases, and Obesity.

\*\* Respiratory Conditions: Asthma and Allergic rhinitis.

\*\*\* Others: including cancers, rheumatoid, Food Allergy, Osteoporosis, Brucellosis, Peptic ulcer, Epilepsy, Multiple Sclerosis, Parkinson, Heart Failure, Chronic Kidney Failure, Cirrhosis, Psychiatric condition, Psoriasis, and Sickle cell anemia.

characteristics of the participants (n=1400).

**Table 2:** General characteristics of the vaccines and their side effects (n=625).

General characteristics and side e	ffects	No.	%
T	Pfizer	325	52%
Type of Vaccine	AstraZeneca-Oxford	300	48%
	Desire and conviction	548	87.7%
Purpose of getting vaccinated	Affordable	12	1.9%
	Job Requirement	30	4.8%
	Family desire	9	1.4%
	Traveling Requirement	22	3.5%
	Protection for the family	1	0.2%
	Preventing covid-19 complication	1	0.2%
	Multiple purposes	1	0.2%
	No purpose	1	0.2%
Presence of side effects post	yes	343	54.9%
vaccination (1 <sup>st</sup> or 2 <sup>nd</sup> dose)	No	282	45.1%
	General:		
Side effects post vaccination	Fever	232	67.7%
Side effects post vaccination	Body Tremor	76	22.2%
(1 <sup>st</sup> or 2 <sup>nd</sup> dose)	Fainting	3	0.9%
	Uterine pain	1	0.3%
	Swelling of mouth and face and neck	6	1.7%
	Systematic:		
	Dermatological <sup>1</sup>	231	67.3%
	Gastrointestinal <sup>2</sup>	129	37.6 %
	Neurological <sup>3</sup>	249	72.6 %
	Respiratory <sup>4</sup>	21	6.2 %
	Musculoskeletal <sup>5</sup>	282	82.3 %

<sup>1</sup> **Dermatological side effects including**: Itching in other than vaccine site, Pain and swelling in injection site.

<sup>2</sup> Gastrointestinal side effects including: Nausea, Vomiting, Diarrhea, and Abdominal pain.

<sup>3</sup> **Neurological side effects including:** Headache, Seizure, Sleep disturbance, Numbness, and Visual disturbance.

<sup>4</sup> **Respiratory side effects including**: Breathing difficulties, Hoarseness, and Throat pain.

<sup>5</sup> Musculoskeletal side effects including: Muscle pain, Chest heaviness, Chest pain, and Back

pain.

# **Table 3:** Acceptance, concerns, and obstaclesrelated to the vaccination.

Acceptance, concerns, and obstacles related to the vaccination		No	%
	Yes	371	47.9%
Take the vaccine after the opportunity to take it	No	142	18.3%
	Maybe	262	33.8%
	Yes	176	22.7%
barriers to taking the vaccine	No	599	77.3%
concerns of the vaccine	Yes	538	38.4%
	No	862	61.6%

 Table 4: The participants' obstacles that prevent

getting the vaccine (n=324).

Virus strains\*\*\*

Vaccine trial and efficacy

Information circulated on social media

The reported obstacles that prevent getting the vaccine	No	%	
1- Parental refuse	12	3.7%	
2- multiple available types of vaccination	46	14.2%	
3- There is conflicting information concerning the vaccine's safety	62	19.1%	
4- not have a health reason to be vaccinated	15	4.6%	
5- lack of information and education about COVID-19 and its	70	21.6%	
vaccination and about how to use the application			
6- Taking a long time to obtain an appointment and being far away	29	9.0%	
from the centers			
7- Having health problems or allergy	58	17.9%	
8- lactating and pregnant women	17	5.2%	
9- Covid-19 was previously diagnosed in less than 6 months	8	2.5%	
10- others	7	2.2%	
Table 5: The participants' concerns regarding			
COVID-19 vaccine (n=1,796).			
The reported concerns of the vaccine	No	%	
Misleading ideas and beliefs *	635	35.4%	
Health concerns**	779	43.4%	

\* **Misleading ideas and beliefs:** Ineffective, harmful, targeted for the elimination of humanity, for experiment, for financial gain, distrust, and lack of conviction in vaccination, lack of need, the strangeness of the disease and the strangeness of its spread

63

213

106

3.5%

11.8%

5.9%

**\*\*Health concerns:** Side effects, it leads to serious diseases, it causes autism, affects genetics, becomes an annual vaccine, leads to death, anaphylaxis, a history of allergies and shortness of breath **\*\*\*Virus strains:** The presence of a new strain, no specific cause of the virus has been known, virus infection after the vaccine

**Table 6:** Receiving COVID-19 vaccination inassociation to the demographics data of theparticipants (n=1400).

		Re	eceived COV	ID-19 Vaco	cine	
Socio-demograp	hic data	Yes		1	No P-val	P-value
	-	Freq	%	Freq	%	-
Gender	Male	263	42.1%	253	32.6%	0.002*
Genuer	Female	362	57.9%	522	67.4%	0.002*
	16-36	259	41.4%	421	54.3%	
Age in years	37-56	252	40.3%	283	36.5%	2.899
	57 and older	114	18.2%	71	9.2%	
NT 41 114	Saudi	603	96.5%	711	91.7%	0.000
Nationality	Non-Saudi	22	3.5%	64	8.3%	0.002*
	Western Region	Western Region 532 85.1% 605	78.1%			
Place of residence	Central Region Eastern Region	72 11	11.5% 1.8%	87 34	11.2% 4.4%	0.001*
	Southern Region	6	1.0%	29	3.7%	
	Northern Region	4	0.6%	20	2.6%	
	Elementary/ Intermediate School	18	2.9%	32	4.1%	
Educational	High school/ Diploma	162	25.9%	215	27.7%	0.332
level	Bachelor's degree	351	56.2%	430	55.5%	
	Master or higher degree	94	15.0%	<i>9</i> 8	12.6%	
Work in	Yes	217	34.7%	212	27.4%	
government	No	171	27.4%	229	29.5%	0.011*
sector	Do not work	237	37.9%	334	43.1%	
History of	Yes	56	9.0%	148	19.1%	9.087
COVID-19	No	569	91.0%	627	80.9%	

Note: P: Pearson  $X^2$  test / \* P < 0.05 (significant).

Table 7: Participar	its' acceptance to take the
vaccine (n=1400).	

Acceptance	Percentage %
Vaccinated or willing	996 (71.1%)
to vaccinate	
Hesitancy	262 (18.7%)
Refusing vaccination	142 (10.2%)

**Table 8:** Different types of barriers wereinvolved in the study.

Barriers	Percentage %
Vaccine variety types and Covid19 strains issues	62 (35.2%)
Safety issues	59 (33.5%)
Health issues	56 (32%)
Convincement of beneficial issues	46 (26.1%)
Vaccine information issue	25 (14.2)
Vaccination application issue	19 (10.8%)
Family Issues	14 (7.9%)
Distance and transport to centres issue	9 (5.2%)
Covid 19 infected	8 (4.8%)
Pregnancy	7 (4.2%)
Breastfeeding	7 (4.8%)
Waiting time issues	6 (3.4%)
Side effects issues	4 (2.4%)
Allergy	3 (1.8%)
Vaccine production issues	1 (0.6%)
Medication Issues	1 (0.6)
Religious Believes	1 (0.6%)

This comparison shows that Arab countries have more concerns about the COVID-19 vaccine than the majority of the rest of the world. Although our study represents one of the first assessments of COVID-19 vaccination behavior in KSA, we acknowledge several limitations. One of these is related to convenient sample conducted on an online platform which may limits the generalizability of the study's results. Additionally, reporting bias could be possible since the study depends on self-reported information that might be influenced by participants' opinions and standards in understanding the items or their proclivity to express their feelings in a certain manner. Lastly, the current study used a cross-sectional design which precludes the ability to make causal conclusions.

#### Conclusion

In conclusion, the current study revealed that the residents of Saudi Arabia had low level of compliance in regard to receive different types of vaccination including flu vaccine and meningitis vaccine. In addition, Female participants showed high levels of compliance to receive COVID-19 vaccination. Knowledge and awareness about COVID-19 are still lacking. Thus, a targeted health educational programs are needed to increase the individual convince and reduce the fears about vaccination, which will contribute to increase the rates of receiving COVID-19 vaccine in the future.

#### List of Abbreviations:

COVID-19: Coronavirus Disease 2019, SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2, WHO: World Health Organization, NRVV: nonreplicating viral vectors, mRNA: messenger ribonucleic acid, US: United States, KSA: Kingdome of Saudi Arabia, CI: Confidence Interval, IRB: Institutional Review Board, UQU: Umm Al-Qura University, SPSS: Statistical Package for the Social Sciences.

### **Conflict of Interest**

None

#### Funding

None

### **References:**

1. Liu Y-C, Kuo R-L, Shih S-R. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328–33.

2. Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020;250(4):271–8.

3. Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infect Dis Model. 2020;5:248–55.

4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020 Feb;395(10223):507–13.

5. Fisk RJ. Barriers to vaccination for coronavirus disease 2019 (COVID-19) control: experience from the United States. Glob Heal J [Internet]. 2021; Available from:

https://www.sciencedirect.com/science/article/pii/S24 14644721000051

6. Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics. 2020;10(17):7821.

7. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11:585354.

8. Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol [Internet]. 2021;222:108634. Available from: https://www.sciencedirect.com/science/article/pii/S15 21661620307944

9. Lazarus J V, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med [Internet]. 2021;27(2):225–8. Available from: https://doi.org/10.1038/s41591-020-1124-9

10. Dean AG, Sullivan KM SM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 3.01 [Internet]. [cited 2021 Jun 25]. Available from: www.OpenEpi.com

11. General Authority for Statistics. Reports and Statistics [Internet]. Unified National Platform. 2021. Available from:

https://www.my.gov.sa/wps/portal/snp/aboutksa/saud iReportsAndStatistics

12. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis [Internet]. 2021;21(7):939–49. Available from: https://www.sciencedirect.com/science/article/pii/S14 73309921002243

13. Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021;9(6):674.

14. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020 Sep;26:100495.

15. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. J Multidiscip Healthc. 2020;13:1657–63.

16. Saied SM, Saied EM, Kabbash IA, Abdo SAE-F. Vaccine hesitancy: Beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students. J Med Virol. 2021 Jul;93(7):4280–91.

17. Pollak Y, Shoham R, Dayan H, Seri OG, Berger I. Background and concurrent factors predicting nonadherence to public health preventive measures during the chronic phase of the COVID-19 pandemic. medRxiv. 2020;2(4):32.

18. Arber BSc Sara MsP, Ginn BSc Jay MsP. Gender differences in informal caring. Health Soc Care Community [Internet]. 1995 Jan 1;3(1):19–31. Available from: https://doi.org/10.1111/j.1365-2524.1995.tb00003.x

19. Alshammary F, Siddiqui AA, Amin J, Ilyas M, Rathore HA, Hassan I, et al. Prevention knowledge and its practice towards COVID-19 among general population of Saudi Arabia: a gender-based perspective. Curr Pharm Des. 2021;27(13):1642–8.

20. Kaadan MI, Abdulkarim J, Chaar M, Zayegh O, Keblawi MA. Determinants of COVID-19 vaccine acceptance in the Arab world: a cross-sectional study. Glob Heal Res policy. 2021 Jul;6(1):23.